文献速递临床试验与 GCP基础与转化研究

肺移植术后病毒载量指导的免疫抑制(VIGILung)随机对照试验研究方案

Viral load-guided immunosuppression after lung transplantation (VIGILung)-study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-01-11

VIGILung 是一项开放标签、随机对照、平行组、多中心试验,纳入肺移植术后 21 至 42 天的成人受者 144 例,按 1:1 随机分为 TTV 监测联合常规治疗药物监测组与常规治疗药物监测组,主要终点为随机化后 12 个月肾小球滤过率变化,旨在评估 TTV 指导免疫抑制的安全性与疗效。

要点

  • TTV 监测作为常规治疗药物监测的附加手段指导肺移植术后免疫抑制。
  • 主要终点为随机化后 12 个月肾小球滤过率变化。
  • 纳入肺移植术后 21 至 42 天成人受者,计划样本量 144 例。

核心结论

  • 该随机对照试验结果可能在不削弱免疫抑制疗效的前提下降低肺移植术后免疫抑制的毒性。
  • 研究结果可推广至所有其他实体器官移植。

研究设计与样本

  • 开放标签、随机对照、平行组、多中心试验,纳入肺移植术后 21 至 42 天成人受者 144 例,按 1:1 随机分组。
  • 试验组在常规他克莫司谷浓度治疗药物监测基础上加用全血 TTV 监测指导免疫抑制,对照组仅用常规治疗药物监测。
  • 随机化后 12 个月评估结局,主要终点为肾小球滤过率变化。

主要发现

  • 原文为研究方案,未报告试验结果。

关键数值与推荐

  • 纳入标准为肺移植术后 21 至 42 天的成人受者。
  • 计划样本量 N = 144,按 1:1 随机分配。
  • 主要终点为随机化后 12 个月肾小球滤过率变化。
  • 次要终点包括其他肾功能指标、移植物功能、急性排斥发生率、慢性肺移植物功能障碍发生率、移植物丢失和感染。
  • 试验注册号 ClinicalTrials.gov NCT04198506,注册日期 2019 年 12 月 12 日。

临床怎么用

  • TTV 监测作为常规治疗药物监测的附加手段,用于指导肺移植术后 CNI 为基础的免疫抑制调整。
  • 临床需关注该策略对肾功能、排斥反应和感染风险的影响,待试验结果验证。

局限性

  • 原文为研究方案,尚无结果数据。
  • 开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunosuppression including high-dose calcineurin inhibitors (CNI) is essential after lung transplantation. Dosing is usually guided by therapeutic drug monitoring adjusted to target trough levels of CNIs to keep the balance between over-dose causing severe toxicity and increased risk of infections or under-dose with a risk of graft injury. Adaptation of CNI-based immunosuppression by monitoring of torque teno virus (TTV), a latent nonpathogenic DNA virus, measured in the whole blood in addition to conventional therapeutic drug monitoring may reduce the toxicity of immunosuppression with similar efficacy. METHODS/DESIGN: An open-label, randomized, controlled, parallel-group, multicenter trial in lung transplant recipients will be conducted to investigate the safety and efficacy of immunosuppression guided by TTV monitoring as an add-on to conventional therapeutic drug monitoring. Adult lung transplant recipients 21 to 42 days after transplantation are eligible to participate. Patients (N = 144) will be randomized 1:1 to the experimental intervention (arm 1: immunosuppression guided by TTV monitoring in addition to conventional therapeutic drug monitoring of tacrolimus trough levels) and control intervention (arm 2: conventional therapeutic drug monitoring). Outcomes will be assessed 12 months after randomization with the change in glomerular filtration rate as the primary endpoint. Secondary endpoints will be additional measurements of renal function, allograft function, incidence of acute rejections, incidence of chronic lung allograft dysfunction, graft loss, and infections. DISCUSSION: The results of this randomized controlled trial may reduce the toxicity of immunosuppression after lung transplantation while maintaining the efficacy of immunosuppression. Study results are transferable to all other solid organ transplantations. TRIAL REGISTRATION: ClinicalTrials.gov NCT04198506 . Registered on 12 December 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gottlieb J, Reuss A, Mayer K, et al. Viral load-guided immunosuppression after lung transplantation (VIGILung)-study protocol for a randomized controlled trial. Trials. 2021. PMID: 33430927. doi:10.1186/s13063-020-04985-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。